Palatin Announces Positive Study Results For Its Drug To Treat Dry Eye Disease

Palatin Technologies, Inc. (PTN) Tuesday announced positive results from an interim analysis of the Phase 3 pivotal study of PL9643, the company's drug candidate for the treatment of patients with dry eye disease.

Based on the review of first 120 patients who had completed the treatment, Data Monitoring Committee (DMC) recommended the study to continue with up to 350 patients, Palatin said.

The Phase 3 study dubbed MELODY-1 is a double-masked and vehicle-controlled study evaluating the safety and efficacy of PL9643 ophthalmic solution, compared to vehicle in patients with moderate-to-severe dry eye disease.

The company said it plans to enroll up to an additional 230 patients in the study. Topline data are expected in the second quarter of calendar 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Foxconn, Apple Inc.'s key iPhone assembler, expects that its major plant in China, which is being hit hard by worker unrest following Covid-19 spread and related restrictions, would restart full production around late December to early January, Reuters reported citing a Foxconn source. Nestle Purina PetCare Co. has recalled a limited amount of certain prescription wet dog food citing labeling error, the U.S. Food and Drug Administration said. The recall involves Purina Pro Plan Veterinary Diets EN Gastroenteric Low Fat or PPVD EN Low Fat wet dog food that comes in 13.4 oz cans. Exportadora Copramar is recalling 1260 cases of James Farm frozen raspberries citing potential to be contaminated with Hepatitis A, the U.S. Food and Drug Administration said. The recall involves James Farm branded frozen raspberries identified by UPC Code: 76069501010 and Lot Code - 22-165.
Follow RTT